Related Experiment Video

Updated: Apr 26, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

Apolipoprotein polymorphism is associated with pro-thrombotic profile in non-demented dyslipidemic subjects

Cláudia N Ferreira1, Maria G Carvalho1, Karina B Gomes1

  • 1Universidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.

Experimental Biology and Medicine (Maywood, N.J.)
|July 31, 2014
PubMed

Insights

Apolipoprotein E2 (apoE2) variants are linked to higher thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Apolipoprotein A5 (apoA5) gene polymorphism correlates with D-dimer in dyslipidemic individuals, but neither impacts cognitive function.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Medicine
  • Neuroscience

Background:

  • Apolipoprotein gene polymorphism influences lipid metabolism and cerebro- and cardio-vascular disease (CCVD) risk.
  • Dyslipidemia and hemostatic abnormalities are critical risk factors for atherosclerosis and CCVD.
  • Understanding the link between apolipoproteins, hemostasis, and cognition is crucial for disease prevention.

Purpose of the Study:

  • To investigate the association between apolipoprotein E (apoE) and apolipoprotein A5 (apoA5) gene variants with hemostatic parameters.
  • To explore the relationship between these apolipoprotein variants, lipid profiles, and cognitive function (MMSE scores).
  • To determine if specific apolipoprotein genotypes predict hemostatic changes or cognitive performance in dyslipidemic and healthy individuals.

Main Methods:

  • Genotyping for apolipoprotein E and A5 gene polymorphisms.
  • Assessment of lipid profiles (total cholesterol, LDL, HDL, triglycerides).
  • Measurement of coagulation markers including D-dimer and thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels.
  • Cognitive function evaluation using the Mini-Mental State Examination (MMSE).
  • Comparison of parameters between 109 dyslipidemic subjects and 107 healthy controls.

Main Results:

  • Thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels were significantly elevated in individuals with the apolipoprotein E2 (apoE2) variant compared to other apoE forms.
  • The apolipoprotein A5 (apoA5) -1131T>C polymorphism was associated with increased D-dimer concentrations in dyslipidemic individuals who were TT homozygous.
  • Mini-Mental State Examination (MMSE) scores showed no correlation with lipid profiles or coagulation parameters in the study population.

Conclusions:

  • Specific apolipoprotein variants, namely apoE and apoA5, demonstrably influence hemostatic parameters.
  • These genetic variations do not appear to affect or predict cognitive performance in individuals who are not diagnosed with dementia.
  • Further research may elucidate the precise mechanisms linking apolipoprotein genetics to hemostatic regulation.

Keywords:
Apolipoprotein-A5 (apoA5)D-dimerapolipoprotein-E (apoE)cerebro- and cardio-vascular disease (CCVD)cognitive performancedementiadyslipidemiagene polymorphismthrombin-activatable fibrinolysis inhibitor (TAFI)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
839
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
719
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
470